Cerus to Present at the Wedbush 2013 Life Sciences Management Access
Conference on August 14, 2013
Wedbush Securities Life Sciences Conference 2013
CONCORD, Calif. -- August 7, 2013
Cerus Corporation (NASDAQ:CERS) announced today that William “Obi” Greenman,
Cerus’ president and chief executive officer, is scheduled to present a
corporate update at the Wedbush 2013 Life Sciences Management Access
Conference in New York at 8:35 am ET on Wednesday, August 14, 2013.
A live webcast of the presentation will be available from the Investor
Relations page of the Cerus web site at http://www.cerus.com/ir. A replay will
be available for approximately two weeks following the completion of the
Cerus Corporation is a biomedical products company focused in the field of
blood safety. The company’s INTERCEPT Blood System has been demonstrated to
inactivate a broad range of viruses, bacteria and parasites that may be
present in donated blood, including established threats such as hepatitis B
and C, HIV, West Nile virus and bacteria, as well as emerging pathogens such
as influenza, malaria and dengue. Cerus currently markets and sells the
INTERCEPT Blood System for both platelets and plasma in Europe, the
Commonwealth of Independent States, the Middle East and selected countries in
other regions around the world. In the United States, Cerus is seeking
regulatory approval of the INTERCEPT Blood System for plasma and platelets.
The INTERCEPT red blood cell system is in clinical development. See
http://www.cerus.com for more information.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.
Lainie Corten, 925-288-6319
Senior Director, Global Marketing & Investor Relations
Press spacebar to pause and continue. Press esc to stop.